Navigation Links
CMV infections affect more than just patients with compromised immune systems, researchers find
Date:7/24/2008

An infection due to a virus called cytomegalovirus (CMV), which most commonly affects people with compromised immune systems, can also affect hospital intensive-care patients who have no immune-system problems, University of Washington researchers have found. CMV infection is also associated with longer hospital and intensive-care unit (ICU) stays independent of other causes, according to the study, published July 23 in JAMA, the Journal of the American Medical Association.

About half of all healthy adults in the United States are exposed to CMV during their life, researchers estimate, and control the infection with their immune system, often without even experiencing symptoms. In some people with reduced immune function, such as organ-transplant recipients, the virus can re-activate in the body and cause serious health problems.

In this study, researchers looked at CMV reactivation in 120 patients with no immune-system problems who were admitted to a hospital ICU. They also analyzed how CMV reactivation affected a patient's long-term health outcomes, including the amount of time the patient had to spend in the hospital or ICU and their risk of death.

The researchers found that CMV reactivation was surprisingly common in ICU patients, with about 30 percent exhibiting an active CMV infection in their bloodstream at various points during the 30-day study period. Even when controlling for other possible variables, CMV reactivation was strongly associated with a longer hospital and ICU stay for patients.

"Other studies have looked at the reactivation rate of CMV, but what makes this study different is that we're looking at people with apparently normal immune systems who were being treated in the ICU for trauma or another medical problem," explained Dr. Ajit Limaye, associate professor of medicine and laboratory medicine at the UW, who led the study. "A substantial number of these patients had CMV reactivate in their bloodstream. What's interesting is that having the virus reactivate was associated with longer ICU and hospital stays, independent of other potential variables."

Longer hospital stays can drive up health-care costs, and can be inconvenient or uncomfortable for patients, Limaye added.

Patients without immune system problems are not typically tested for CMV. However, despite the study findings, Limaye said, it would be premature to start routine testing of ICU patients for reactivation of the virus.

First, the researchers will need to see whether using anti-viral drugs to treat regular-immunity ICU patients can help cut down on reactivation of CMV, or whether it can cut down on the length of hospital stays for those patients with the reactivated virus.

"There are side effects associated with the treatment for CMV, and CMV might simply be a marker, rather than a cause," Limaye explained. "Because of that, we need to test the theory that by treating CMV we can improve the endpoint -- the length of stay in the hospital."

If the planned clinical trial shows that treatment can cut down on CMV reactivation and reduce hospital stays for those patients, Limaye said, it could bring about a new paradigm for improving outcomes for hospital ICU patients. ICUs are typically focused on pulmonary and critical care, he explained, but CMV is an infectious-disease issue.


'/>"/>

Contact: Justin Reedy
jreedy@u.washington.edu
206-685-0382
University of Washington
Source:Eurekalert

Related biology news :

1. Analysis of RNA role in spreading disease advances study of damaging plant infections
2. Bacterial infections in premature babies more common than previously realized
3. New drug targets may fight tuberculosis and other bacterial infections in novel way
4. Bacteria that cause urinary tract infections invade bladder cells
5. Best treatment identified to reduce deadly Staph infections
6. Gamma interferon could aid fight against fungal infections
7. Scripps research team blocks bacterial communication system to prevent deadly staph infections
8. Handbook helps parents deal with childhood infections
9. Evidence of a relationship between swimming babies and infections
10. Nutrient pollution drives frog deformities by ramping up infections, says CU-Boulder study
11. UCLA/VA partners with ASU to advance biosensor technology for urinary tract infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology: